We are live on
!
Find out more
PVI
Pura Vida Investments Portfolio holdings
AUM
$14.9M
1-Year Est. Return
38.76%
This Fund
S&P 500
This Quarter
Est. Return
+12.8%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$3.21B
AUM Growth
-$296M
(-8.4%)
Cap. Flow
-$592M
Cap. Flow
% of AUM
-18.42%
Top 10 Holdings %
Top 10 Hldgs %
43.24%
Holding
304
New
89
Increased
36
Reduced
82
Closed
88
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AtaiBeckley Inc
ATAI
|
+$25.3M |
| 2 |
Agilon Health
AGL
|
+$13.5M |
| 3 |
Eli Lilly
LLY
|
+$13.2M |
| 4 |
Privia Health
PRVA
|
+$12.8M |
| 5 |
Lantheus
LNTH
|
+$12.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$23.9M |
| 2 |
Vericel Corp
VCEL
|
+$20.8M |
| 3 |
Align Technology
ALGN
|
+$19M |
| 4 |
SI-BONE Inc
SIBN
|
+$17.5M |
| 5 |
STAAR Surgical
STAA
|
+$14.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 34.64% |
| 2 | Industrials | 1.41% |
| 3 | Materials | 0.54% |
| 4 | Financials | 0.48% |
| 5 | Consumer Staples | 0.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
908 Devices
MASS
$414M
| $6.24M | 0.19% |
161,059
+12,292
| +8% | +$557K |
|
102
Cullinan Oncology
CGEM
$1.26B
| $6.2M | 0.19% |
240,798
+24,168
| +11% | +$743K |
|
|
EXAS
103
PUT
DELISTED
Exact Sciences
EXAS
| $6.05M | 0.19% |
48,700
+18,700
| +62% | +$2.23M |
|
104
CALL
Quanterix
QTRX
$124M
| $5.87M | 0.18% |
+100,000
| New | +$5.8M |
|
|
ARYD
105
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
| $5.74M | 0.18% |
535,179
-8,985
| -2% | -$95.8K |
|
|
KYNB
106
PUT
Kyntra Bio
KYNB
$28.6M
| $5.67M | 0.18% |
+8,520
| New | +$4.91M |
|
107
Regeneron Pharmaceuticals
REGN
$82.1B
| $5.58M | 0.17% |
+10,000
| New | +$5.07M |
|
|
FOLD
108
CALL
DELISTED
Amicus Therapeutics
FOLD
| $5.47M | 0.17% |
567,300
-55,200
| -9% | -$539K |
|
109
Neuropace
NPCE
$513M
| $5.45M | 0.17% |
+229,264
| New | +$5.32M |
|
|
ICAD
110
DELISTED
iCAD Inc
ICAD
| $5.37M | 0.17% |
310,278
-77,915
| -20% | -$1.37M |
|
111
Avita Medical
RCEL
$254M
| $5.31M | 0.17% |
258,951
-124,638
| -32% | -$2.46M |
|
112
CALL
Quince Therapeutics
QNCX
$33.3M
| $5.3M | 0.17% |
+500
| New | +$4.19M |
|
|
CMLTU
113
DELISTED
CM Life Sciences III Inc. Unit
CMLTU
| $5.29M | 0.16% |
+483,164
| New | +$5.21M |
|
|
RACB
114
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
| $5.28M | 0.16% |
520,180
-13,120
| -2% | -$138K |
|
|
KYNB
115
CALL
Kyntra Bio
KYNB
$28.6M
| $5.2M | 0.16% |
+7,804
| New | +$4.5M |
|
|
HOLX
116
PUT
DELISTED
Hologic
HOLX
| $5M | 0.16% |
75,000
-25,000
| -25% | -$1.67M |
|
117
PUT
Teladoc Health
TDOC
$1.24B
| $4.99M | 0.16% |
+30,000
| New | +$4.86M |
|
|
NVRO
118
DELISTED
NEVRO CORP.
NVRO
| $4.97M | 0.15% |
+30,000
| New | +$4.68M |
|
119
Zentalis Pharmaceuticals
ZNTL
$295M
| $4.84M | 0.15% |
91,069
+34,293
| +60% | +$1.84M |
|
120
Glaukos
GKOS
$10.7B
| $4.67M | 0.15% |
55,000
-37,500
| -41% | -$3.08M |
|
|
CMAX
121
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $4.67M | 0.15% |
12,054
-180
| -1% | -$71.5K |
|
|
AKYA
122
DELISTED
Akoya BioSciences
AKYA
| $4.63M | 0.14% |
+239,566
| New | +$4.95M |
|
123
Turning Point Brands
TPB
$1.77B
| $4.63M | 0.14% |
101,059
-116,484
| -54% | -$5.39M |
|
|
VRAY
124
CALL
DELISTED
ViewRay, Inc.
VRAY
| $4.62M | 0.14% |
+700,000
| New | +$3.73M |
|
125
CALL
Neurocrine Biosciences
NBIX
$16.5B
| $4.6M | 0.14% |
+47,300
| New | +$4.53M |
|
Similar funds
BCA
RC
DOFI
SCI
LPC
GBCP
SCTC
M
Pura Vida Investments's Q2 2021 Portfolio in Review
As of Q2 2021, Pura Vida Investments held 304 positions worth $3.21B, down 8.4% from $3.51B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Pura Vida Investments withdrew a net $592M in Q2 2021, closing 88 positions and reducing 82 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $23.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 33% a quarter earlier, followed by Industrials and Materials.
Against the trend, Pura Vida Investments opened a new position in AtaiBeckley Inc worth $23.2M.
- Pura Vida Investments's largest Q2 2021 buy was AtaiBeckley Inc: 1,371,824 shares worth $23.2M.
- Pura Vida Investments added most to Quotient Limited Ordinary Shares in Q2 2021, an estimated $9.15M increase.
- Pura Vida Investments's biggest Q2 2021 reduction was STAAR Surgical, cutting an estimated $14.6M.
- Pura Vida Investments fully exited Alexion Pharmaceuticals in Q2 2021, selling an estimated $23.9M.
- Pura Vida Investments's ten largest holdings make up 43% of its $3.21B portfolio in Q2 2021.
- Pura Vida Investments opened 89 new positions and closed 88 in Q2 2021.
- Pura Vida Investments's portfolio value fell 8.4% quarter-over-quarter to $3.21B.
Based on Pura Vida Investments's 13F filing for Q2 2021, filed 16 Aug 2021.